Targovax ASA: Registration of share capital increase following exercise of employee options
November 21, 2016 08:10 ET
|
Targovax ASA
Reference is made to the notice of 4 November 2016 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of...
Targovax ASA: Exercise of employee share options in Targovax ASA
November 21, 2016 01:00 ET
|
Targovax ASA
Reference is made to stock exchange notice of 4 November 2016 regarding increase of the share capital in Targovax ASA (the "Company") relating to exercise of employee options and settlement of...
Targovax ASA: Mandatory notification of trade by primary insider
November 18, 2016 01:00 ET
|
Targovax ASA
Jon Amund Eriksen, Chief Technology Innovation Officer of Targovax ASA, has on 17 November 2016 acquired 3,951 shares in Targovax ASA at a price of NOK 9.60 per share. Following the transaction, Jon...
Targovax ASA: Third quarter 2016 results
November 17, 2016 01:05 ET
|
Targovax
OSLO, Norway, Nov. 17, 2016 (GLOBE NEWSWIRE) -- Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target,...
Targovax to present at forthcoming conference
November 16, 2016 01:09 ET
|
Targovax
OSLO, Norway, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target,...
Targovax granted European Patent for ONCOS platform lead product, ONCOS-102
November 10, 2016 01:10 ET
|
Targovax
Extends protection following grant of ONCOS-102 US patent in May Oslo, Norway, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company...
Targovax ASA: Invitation to third quarter 2016 results presentation Thursday 17 November
November 08, 2016 01:10 ET
|
Targovax
OSLO, Norway, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immuno-oncology therapies to target, primarily,...
Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
November 04, 2016 02:01 ET
|
Targovax
The board of directors of Targovax ASA (the "Company") has on 3 November 2016, in accordance with the authorisations granted by the general meeting 13 April 2016, resolved: to increase the share...
Targovax announces appointment of Oystein Soug as CEO
November 02, 2016 02:07 ET
|
Targovax ASA
OSLO, Norway, Nov. 2, 2016 (GLOBE NEWSWIRE) -- Targovax ASA ("Targovax" or "the Company"; OSE:TRVX), a clinical stage company focused on developing and commercializing immuno-oncology therapies to...
Targovax to Present at the ESGCT/ISSCR Stem Cells & Gene Therapy Symposium
October 17, 2016 02:03 ET
|
Targovax ASA
OSLO, Norway, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Targovax (OSE: TRVX, or "the Company"), a clinical stage company developing targeted immunotherapy treatments for cancer patients, announces that the...